ImmunoGen CEO: Solving Cancer’s Access Challenge With Data, Differentiation And A Big Dose of Bipartisanship
ImmunoGen CEO Mark Enyedy, a leading proponent of targeted ADC oncologics, explains to In Vivo how high risk – and dogged resilience – are central features of a challenging innovative landscape in cancer today. Despite some recent setbacks on the road to commercialization, science will continue to transform, bolstered by the industry's financial commitments; revolutionary new data sources, validated by patient-centered outcomes; and that persistent human intangible called hope.
You may also be interested in...
Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.
Insights from Gates Medical Research Institute CEO Dr. Penny Heaton.
In Vivo visits Gates Medical Research Institute CEO Dr. Penny Heaton to review its first pipeline of drugs and vaccines to attack four of the world’s biggest killers: TB, malaria, enteric diseases and other conditions affecting maternal, newborn and child health.